| Drug Name |
Rilonacept |
| Drug ID |
BADD_D01939 |
| Description |
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. |
| Indications and Usage |
Rilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AC04 |
| DrugBank ID |
DB06372
|
| KEGG ID |
D06635
|
| MeSH ID |
C531377
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D09DBY
|
| NDC Product Code |
73604-914; 65044-7168 |
| UNII |
8K80YB5GMG
|
| Synonyms |
rilonacept | interleukin-1 Trap |
